Interplay between modified vaccinia virus ankara and dendritic cells: Phenotypic and functional maturation of bystander dendritic cells

Journal of Virology

Volumn 85, Issue 11, 2011, Pages 5532-5545

  Pascutti, María F ^a,d   Rodríguez, Ana M ^a   Falivene, Juliana ^a   Giavedoni, Luis ^b   Drexler, Ingo ^c   Gherardi, M Magdalena ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b SOUTHWEST NATIONAL PRIMATE RESEARCH CENTER   (United States)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CD86 ANTIGEN; CHEMOKINE; CYTOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HLA DR ANTIGEN; INTERFERON; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; BYSTANDER EFFECT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL FUNCTION; CELL MATURATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; HUMAN; HUMAN CELL; MODIFIED VACCINIA VIRUS ANKARA; MONOCYTE; NONHUMAN; PERIPHERAL LYMPHOCYTE; PHENOTYPE; POXVIRUS; POXVIRUS INFECTION; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; T LYMPHOCYTE ACTIVATION; UPREGULATION; VIRUS CELL INTERACTION;

ANTIGENS, CD86; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CYTOKINES; DENDRITIC CELLS; HLA-DR ANTIGENS; HUMANS; INTERFERON-GAMMA; TUMOR NECROSIS FACTOR-ALPHA; VACCINIA VIRUS;

POXVIRIDAE; VACCINIA VIRUS ANKARA;

EID: 79956078254     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02267-10     Document Type: Article

References (50)

1. Antoine, G., F. Scheiflinger, F. Dorner, and F. G. Falkner. 1998. The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 244:365-396.
2. Aravalli, R. N., S. Hu, T. N. Rowen, J. M. Palmquist, and J. R. Lokensgard. 2005. Cutting edge: TLR2-mediated proinflammatory cytokine and chemokine production by microglial cells in response to herpes simplex virus. J. Immunol. 175:4189-4193.
3. Arrode, G., C. Boccaccio, J. P. Abastado, and C. Davrinche. 2002. Crosspresentation of human cytomegalovirus pp65 (UL83) to CD8+ T cells is regulated by virus-induced, soluble-mediator-dependent maturation of dendritic cells. J. Virol. 76:142-150.
4. Behboudi, S., A. Moore, S. C. Gilbert, C. L. Nicoll, and A. V. Hill. 2004. Dendritic cells infected by recombinant modified vaccinia virus Ankara retain immunogenicity in vivo despite in vitro dysfunction. Vaccine 22:4326-4331.
5. Belyakov, I. M., et al. 2003. Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses. Proc. Natl. Acad. Sci. U. S. A. 100:9458-9463.
6. Belz, G. T., et al. 2004. Cutting edge: conventional CD8 alpha+ dendritic cells are generally involved in priming CTL immunity to viruses. J. Immunol. 172:1996-2000.
7. Berghall, H., et al. 2006. The interferon-inducible RNA helicase, mda-5, is involved in measles virus-induced expression of antiviral cytokines. Microbes Infect. 8:2138-2144.
8. Brandler, S., et al. 2010. Preclinical studies of a modified vaccinia virus Ankara-based HIV candidate vaccine: antigen presentation and antiviral effect. J. Virol. 84:5314-5328.
9. Carvalho, L. P., E. J. Pearce, and P. Scott. 2008. Functional dichotomy of dendritic cells following interaction with Leishmania braziliensis: infected cells produce high levels of TNF-alpha, whereas bystander dendritic cells are activated to promote T cell responses. J. Immunol. 181:6473-6480.
10. Chahroudi, A., et al. 2006. Differences and similarities in viral life cycle progression and host cell physiology after infection of human dendritic cells with modified vaccinia virus Ankara and vaccinia virus. J. Virol. 80:8469-8481.
11. Corey, L., M. J. McElrath, and J. G. Kublin. 2009. Post-step modifications for research on HIV vaccines. AIDS 23:3-8.
12. Cruikshank, W. W., H. Kornfeld, and D. M. Center. 2000. Interleukin-16. J. Leukoc. Biol. 67:757-766.
13. Currier, J. R., et al. 2002. A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. J. Immunol. Methods 260:157-172.
14. Currier, J. R., et al. 2010. Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate. PLoS One 5:e13983.
15. Delaloye, J., et al. 2009. Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome. PLoS Pathog. 5:e1000480.
16. Drexler, I., C. Staib, and G. Sutter. 2004. Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential? Curr. Opin. Biotechnol. 15:506-512.
17. Drillien, R., D. Spehner, and D. Hanau. 2004. Modified vaccinia virus Ankara induces moderate activation of human dendritic cells. J. Gen. Virol. 85:2167-2175.
18. Dufour, J. H., et al. 2002. IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. J. Immunol. 168:3195-3204.
19. Engelmayer, J., et al. 1999. Vaccinia virus inhibits the maturation of human dendritic cells: a novel mechanism of immune evasion. J. Immunol. 163: 6762-6768.
20. Gasteiger, G., W. Kastenmuller, R. Ljapoci, G. Sutter, and I. Drexler. 2007. Cross-priming of cytotoxic T cells dictates antigen requisites for modified vaccinia virus Ankara vector vaccines. J. Virol. 81:11925-11936.
21. Giavedoni, L. D. 2005. Simultaneous detection of multiple cytokines and chemokines from nonhuman primates using Luminex technology. J. Immunol. Methods 301:89-101.
22. Gomez, C. E., J. L. Najera, M. Krupa, and M. Esteban. 2008. The poxvirus vectors MVA and NYVAC as gene delivery systems for vaccination against infectious diseases and cancer. Curr. Gene Ther. 8:97-120.
23. Guerra, S., et al. 2007. Distinct gene expression profiling after infection of immature human monocyte-derived dendritic cells by the attenuated poxvirus vectors MVA and NYVAC. J. Virol. 81:8707-8721.
24. Ignatius, R., et al. 2000. Canarypox virus-induced maturation of dendritic cells is mediated by apoptotic cell death and tumor necrosis factor alpha secretion. J. Virol. 74:11329-11338.
25. Kamgang, R. K., et al. 2008. Using distinct molecular signatures of human monocytes and dendritic cells to predict adjuvant activity and pyrogenicity of TLR agonists. Med. Microbiol. Immunol. 197:369-379.
26. Kastenmuller, W., et al. 2006. Infection of human dendritic cells with recombinant vaccinia virus MVA reveals general persistence of viral early transcription but distinct maturation-dependent cytopathogenicity. Virology 350:276-288.
27. Lane, J. M., and J. Goldstein. 2003. Evaluation of 21st-century risks of smallpox vaccination and policy options. Ann. Intern. Med. 138:488-493.
28. Lehmann, M. H., et al. 2009. Modified vaccinia virus Ankara triggers chemotaxis of monocytes and early respiratory immigration of leukocytes by induction of CCL2 expression. J. Virol. 83:2540-2552.
29. Le Nouen, C., et al. 2009. Infection and maturation of monocyte-derived human dendritic cells by human respiratory syncytial virus, human metapneumovirus, and human parainfluenza virus type 3. Virology 385:169-182.
30. Li, P., et al. 2005. Disruption of MHC class II-restricted antigen presentation by vaccinia virus. J. Immunol. 175:6481-6488.
31. Lindell, D. M., T. E. Lane, and N. W. Lukacs. 2008. CXCL10/CXCR3-mediated responses promote immunity to respiratory syncytial virus infection by augmenting dendritic cell and CD8(+) T cell efficacy. Eur. J. Immunol. 38:2168-2179.
32. Liu, L., R. Chavan, and M. B. Feinberg. 2008. Dendritic cells are preferentially targeted among hematolymphocytes by modified vaccinia virus Ankara and play a key role in the induction of virus-specific T cell responses in vivo. BMC Immunol. 9:15.
33. Malkin, A. J., A. McPherson, and P. D. Gershon. 2003. Structure of intracellular mature vaccinia virus visualized by in situ atomic force microscopy. J. Virol. 77:6332-6340.
34. Moutaftsi, M., et al. 2010. Uncovering the interplay between CD8, CD4 and antibody responses to complex pathogens. Future Microbiol. 5:221-239.
35. Nightingale, Z. D., C. Patkar, and A. L. Rothman. 2008. Viral replication and paracrine effects result in distinct, functional responses of dendritic cells following infection with dengue 2 virus. J. Leukoc. Biol. 84:1028-1038.
36. Norder, M., et al. 2010. Modified vaccinia virus Ankara exerts potent immune modulatory activities in a murine model. PLoS One 5:e11400.
37. Padovan, E., G. C. Spagnoli, M. Ferrantini, and M. Heberer. 2002. IFNalpha2a induces IP-10/CXCL10 and MIG/CXCL9 production in monocytederived dendritic cells and enhances their capacity to attract and stimulate CD8+ effector T cells. J. Leukoc. Biol. 71:669-676.
38. Pierre, P., et al. 1997. Developmental regulation of MHC class II transport in mouse dendritic cells. Nature 388:787-792.
39. Pollara, G., et al. 2004. Herpes simplex virus type-1-induced activation of myeloid dendritic cells: the roles of virus cell interaction and paracrine type I IFN secretion. J. Immunol. 173:4108-4119.
40. Rehm, K. E., et al. 2009. Vaccinia virus decreases major histocompatibility complex (MHC) class II antigen presentation, T-cell priming, and peptide association with MHC class II. Immunology 128:381-392.
41. Rudd, B. D., G. D. Luker, K. E. Luker, R. S. Peebles, and N. W. Lukacs. 2007. Type I interferon regulates respiratory virus infected dendritic cell maturation and cytokine production. Viral Immunol. 20:531-540.
42. Seet, B. T., et al. 2003. Poxviruses and immune evasion. Annu. Rev. Immunol. 21:377-423.
43. Servet-Delprat, C., et al. 2000. Consequences of Fas-mediated human dendritic cell apoptosis induced by measles virus. J. Virol. 74:4387-4393.
44. Sutter, G., and B. Moss. 1992. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc. Natl. Acad. Sci. U. S. A. 89:10847-10851.
45. Sutter, G., and C. Staib. 2003. Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery. Curr. Drug Targets Infect. Disord. 3:263-271.
46. Waibler, Z., et al. 2007. Modified vaccinia virus Ankara induces Toll-like receptor-independent type I interferon responses. J. Virol. 81:12102-12110.
47. Xu, R., A. J. Johnson, D. Liggitt, and M. J. Bevan. 2004. Cellular and humoral immunity against vaccinia virus infection of mice. J. Immunol. 172:6265-6271.
48. Yao, Y., et al. 2007. Vaccinia virus infection induces dendritic cell maturation but inhibits antigen presentation by MHC class II. Cell. Immunol. 246:92-102.
49. Yeh, N., et al. 2010. Tc17 cells are capable of mediating immunity to vaccinia virus by acquisition of a cytotoxic phenotype. J. Immunol. 185:2089-2098.
50. Zhu, J., J. Martinez, X. Huang, and Y. Yang. 2007. Innate immunity against vaccinia virus is mediated by TLR2 and requires TLR-independent production of IFN-beta. Blood 109:619-625.